Host airway and alveolar epithelial cell genome

The host airway and alveolar epithelial cell genome refers to the complete set of genetic information contained within the specialized cells lining the human respiratory tract, including ciliated cells, goblet cells, and Type I and II pneumocytes (PubMed: 32289261). This genome serves as the fundamental blueprint for respiratory physiology, orchestrating the production of the mucosal barrier, facilitating gas exchange, and regulating local immune responses. While not a discrete therapeutic target in traditional pharmacology, specific loci within this genome are the focus of advanced genetic interventions; for example, mutations in the CFTR gene are targeted by gene-editing or gene-replacement strategies to treat cystic fibrosis (PubMed: 31553641). Additionally, the genome encodes critical host factors such as ACE2 and TMPRSS2, which are exploited by respiratory viruses like SARS-CoV-2 for cellular entry and replication (PubMed: 32142651). Because this term encompasses the entire DNA complement of multiple cell types rather than a specific protein or pathway, it is considered an overly broad and non-specific designation for a drug target. Consequently, it is categorized as an incorrect target for standard drug-receptor interaction models, though it remains the primary landscape for pulmonary precision medicine.

Other names

Host respiratory genomeAirway epithelial cell genomeAlveolar epithelial cell genomeRespiratory epithelial genomic DNA

Modification of host genetic material via gene editing, gene addition, or gene silencing to restore cellular function or prevent viral replication.